Home › Burkitt-lymfoom › Ohio › Cincinnati
Burkitt-lymfoom klinische studies in Cincinnati, OH
12 studies voor Burkitt-lymfoom zoeken deelnemers op locaties in en rond Cincinnati (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RekruterenFase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
RekruterenFase 3
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · 15 mijl verwijderd
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekruterenObservatieonderzoek
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
RekruterenFase 2
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · 15 mijl verwijderd
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RekruterenFase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RekruterenFase 3
- University of Cincinnati Medical Center, Cincinnati
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
RekruterenFase 3
- Cincinnati Children's Hospital Medical Center (Data Collection Only), Cincinnati
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RekruterenFase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RekruterenFase 3
- Cincinnati Children's Hospital Medical Center, Cincinnati
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
RekruterenFase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
RekruterenFase 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
RekruterenFase 1
- University of Cincinnati, Cincinnati
Burkitt-lymfoom studies in andere steden
- Houston, TX21 studies
- Milwaukee, WI16 studies
- Philadelphia, PA16 studies
- New York City, NY14 studies
- Chicago, IL14 studies
- Atlanta, GA12 studies
- Seattle, WA11 studies
- Boston, MA10 studies
- Durham, NC10 studies
- Aurora, CO10 studies
- Los Angeles, CA10 studies
- Kansas City, MO10 studies
Andere studies in Cincinnati
- Niet-kleincellige longkanker35 studies
- Kanker (alle vormen)27 studies
- Borstkanker25 studies
- Hartfalen24 studies
- Colorectale kanker21 studies
- Acute myeloïde leukemie20 studies
- Metastatische kanker20 studies
- Eierstokkanker19 studies
- Longkanker19 studies
- Obesitas19 studies
- Prostaatkanker18 studies
- Multipel myeloom17 studies
Van ClinicalTrials.gov, gegevens opgehaald op 5 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.